Physician profile
Jijo Wang
NPI 1275980807
$6,594.16
in general payments reported to CMS, 2019-2025
24 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.91 · 2020: $293 · 2021: $548 · 2022: $177 · 2023: $308 · 2024: $1,972 · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,505.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,935.24 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Alcon Vision LLC | $1,076.23 | 2021-2025 | Tryptyr, Rocklatan, Clareon |
| Sight Sciences, INC. | $788.26 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Tarsus Pharmaceuticals, INC. | $475.33 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $315.63 | 2024-2025 | Acthar |
| Amgen INC. | $284.48 | 2025 | Tepezza |
| Eyepoint US, INC. | $240.33 | 2021 | |
| Apellis Pharmaceuticals, INC. | $231.68 | 2023-2024 | Syfovre |
| Allergan, INC. | $176.76 | 2019-2020 | |
| Glaukos Corporation | $174.52 | 2020-2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Astellas Pharma US INC | $132.56 | 2024 | Izervay |
| Aerie Pharmaceuticals, INC. | $122.64 | 2021 | |
| Carl Zeiss Meditec, INC. | $118.81 | 2021 | |
| Ocular Therapeutix, INC. | $115.18 | 2024-2025 | Dextenza |
| Oyster Point Pharma, INC. | $112.53 | 2023-2024 | Tyrvaya, Ryzumvi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $104.50 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $65.19 | 2020-2022 | |
| Horizon Therapeutics Plc | $24.16 | 2022 | |
| Thea Pharma INC. | $19.60 | 2023 | |
| Rayner Intraocular Lenses Limited | $18.98 | 2022 | |
| Rxsight INC | $18.28 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
| Abbvie INC. | $15.43 | 2023 | Durysta |
| Kala Pharmaceuticals, INC. | $14.00 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jijo Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.